Castle Biosciences INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Portolan Capital Management and George McCabe have filed an amendment reporting a 4.45% beneficial ownership stake in Castle Biosciences, Inc.
NASDAQ
RTW Investments, LP and Roderick Wong have reported a beneficial ownership of 9.3% in Castle Biosciences, Inc., totaling 2,758,335 shares as of March 31, 2026.
NASDAQ
The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Castle Biosciences Inc. due to an internal corporate realignment.
NASDAQ
RTW Investments, LP and Roderick Wong, M.D. have disclosed a 7.2% beneficial ownership stake in Castle Biosciences, Inc. as of December 31, 2025.
NASDAQ
Dimensional Fund Advisors LP has disclosed a 3.9% passive ownership stake in Castle Biosciences Inc. common stock as of December 31, 2025.
NASDAQ
Dimensional Fund Advisors LP has reported a 5.1% beneficial ownership stake in Castle Biosciences Inc. common stock, held in the ordinary course of business.
NASDAQ
Wasatch Advisors LP has filed an Amendment No. 6 to Schedule 13G, reporting beneficial ownership of 3.5% of Castle Biosciences Inc.'s common stock as of March 31, 2025.
NASDAQ
BlackRock, Inc. has filed an Amendment No. 4 to Schedule 13G, reporting a beneficial ownership of 8.2% of Castle Biosciences Inc.'s common stock as of March 31, 2025.
NASDAQ
Portolan Capital Management, LLC and its manager George McCabe have disclosed a passive beneficial ownership of 5.65% in Castle Biosciences, Inc. common stock.
NASDAQ
The Vanguard Group has filed an amended Schedule 13G, reporting a 6.54% passive beneficial ownership stake in Castle Biosciences Inc. as of December 31, 2024.